PER.C6 cell line细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心

PER.C6 cell line细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心

The PER.C6 cell line is a superduper and commercial available manufacturing system that can be used to produce a variety of biopharmaceutical products, including vaccines, gene therapy products, antibodies and other therapeutic proteins. Up to now, more than fourteen biopharmaceutical products utilizing the PER.C6 cell line are in Phase I/II clinical trials, for example, the MOR103 mAb, a human IgG antibody against granulocyte macrophage colony-stimulating factor in clinical development for the treatment of rheumatoid arthritis and multiple sclerosis; another example is CL184, a combination of two monoclonal antibodies (mAbs) against the rabies virus, which has been granted FDA fast-track approval status. Furthermore, mostly PER.C6-based vaccines against tuberculosis, malaria and HIV are also currently in clinical trials.

PER.C6 cell lines

The PER.C6 cell line is derived from human embryonic retinal cells, originally from the retinal tissue of an 18 week old fetus aborted in 1985 and further developed and prepared as cell line by transfection with defined E1 region of the adenovirus type 5 followed by selection for transfectants with an immortal phenotype. At the beginning, this cell line was mainly applied for the production of human adenovirus vectors for use in vaccine development and gene therapy, and further optimization makes PER.C6 become a superexcellent host cell line for large-scale industrial production of therapeutic proteins, especially the human IgG. The PER.C6 expression system has significant advantages including:
(1) Superior yield: PER.C6 requires no amplification of inserted genes to deliver stable clones with high levels of protein expression and a low copy number is sufficient to retain stable and efficient protein expression;
(2) Adequate human post-translational modifications (PTMs): PER.C6 produces therapeutic recombinant proteins with adequate human PTMs, generating none potentially immunogenic glycan structures.
(3) High transfect ability: PER.C6 cells are well-suited for both transient and stable transfection expression, allowing for rapid screening of product leads.
(4) High safety: PER.C6 cell line has a clear origin and transformation background, which does not contain any viruses or prions and passed all safety tests, including retrovirus assays.
(5) Simple and flexible culture condition: PER.C6 cells grow well in suspension serum-free culture that is free of any animal-derived protein and they can also suit all culture scales, from roller bottles to very large-scale bioreactors.

BioVector NTCC Inc. is a pioneer and undisputed global leader in recombinant antibody manufacture and service, we have years of experience in using PER.C6 cell line to produce various recombinant antibodies by both transient and stable transfection expression approaches. With state-of-the-art equipment and experienced human cell line specialists, BioVector NTCC Inc. is committed to delivering the most suitable PER.C6 cell line service to meet customers’ specific requirements.

BioVector NTCC Inc. is capable of providing the following stable cell lines for various proteins expression:

➢ CHO cell lines: GS system, DHFR system;
➢ BHK cell line;
➢ Mouse myeloma cell lines: NS0, SP2/0, etc.
➢ Rat myeloma cell lines: YB2/0, etc.
➢ Human cell lines: HEK293 and its derivatives, HT-1080, Huh-7, PER.C6 , etc.


Supplier来源:BioVector NTCC Inc.
TEL电话:+86-010-53513060
Website网址: http://www.biovector.net